1.Metabolic Syndrome and Steroid: 11 -Hydroxysteroid Dehydrogenases (11 -HSDs).
Journal of Korean Society of Endocrinology 2004;19(4):289-299
No abstrat available.
Oxidoreductases*
2.Metabolic Syndrome and Steroid: 11 -Hydroxysteroid Dehydrogenases (11 -HSDs).
Journal of Korean Society of Endocrinology 2004;19(4):289-299
No abstrat available.
Oxidoreductases*
3.Glucose-6 Phosphate Dehydrogenase Deficiency.
Meen Jai LEE ; Sang Eun LEE ; Dong Whan LEE ; Sang Jhoo LEE ; Sang Chul PARK
Journal of the Korean Pediatric Society 1990;33(2):212-219
No abstract available.
Oxidoreductases*
4.A Study on the Laetic Dehydrogenase Isoenzyme of the Rabbit Kidney.
Korean Journal of Urology 1972;13(3):151-161
No abstract available.
Kidney*
;
Oxidoreductases*
5.Molecular Cloning and Expression of Human Placental 3beta - Hydroxysteroid Dehydrogenase.
Seon Hee OH ; Jae Min OH ; Jeong Joong KIM ; Min Kyu CHOI ; Seung Taeck PARK ; Yeun Tai CHUNG
Korean Journal of Physical Anthropology 1998;11(2):261-270
No abstract available.
Cloning, Molecular*
;
Humans*
;
Oxidoreductases*
6.Lactic dehydrogenase activity in serum and urine of children with renal diseases.
Journal of the Korean Pediatric Society 1985;28(2):147-153
No abstract available.
Child*
;
Humans
;
Oxidoreductases*
7.Compound Heterozygous Pathogenic Variants of the 15-Hydroxyprostaglandin Dehydrogenase Gene in a Patient With Hypertrophic Osteoarthropathy: First Case in Korea.
Mi Ra RYU ; Ji Hyun YANG ; Sang Youl RHEE ; Ahra CHO ; Seong Yoon KIM ; Chang Seok KI
Annals of Laboratory Medicine 2019;39(1):105-108
No abstract available.
Humans
;
Korea*
;
Oxidoreductases*
8.Clinical Efficacy of Pravastatin in Patients with Hypercholesterolemia.
June Soo KIM ; Ki Hoon HAN ; Seung Woo PARK ; Joon Kyung BANG ; Suk Keun HONG ; Dae Won SOHN ; Byung Hee OH ; Myoung Mook LEE ; Young Bae PARK ; Yun Shik CHOI ; Jung Don SEO ; Young Woo LEE
Korean Circulation Journal 1992;22(1):113-120
BACKGROUND: This study was designed to evaluate the clinical efficacy of pravastatin, HMG-CoA reductase inhibitor, in patients with hypercholesterolemia. Methods and RESULTS: Pravastatin 5 mg was administered twice daily for 12 weeks in twenty five patients(12 male, 13 female) with hypercholesterolemia(>240 mg/dl). Compared with pretreatment levels, pravastatin significantly decreased levels of total cholesterol(281+/-41mg/dl versus 218+/-31mg/dl) by 22% and LDL-cholesterol(199+/-46mg/dl versus 137+/-37mg/dl) by 31% with significantly decreased total-cholesterol/HDL-cholesterol ratio(7.1+/-3.0 versus 5.1+/-1.6) and LDL-cholesterol/HDL-cholesterol ratio(5.1+/-2.5 versus 3.3+/-1.4) (p<0.005, respectively). During pravastatin treatment, the level of Apo B(164+/-38mg/dl versus 123+/-20mg/dl) was decreased significantly by 24% with significantly decreased Apo B/Apo A-1 ratio(1.4+/-0.5 versus 1.0+/-0.3) (p<0.005, respectively). No serious side effects were found. CONCLUSIONS: Results from the present study show that pravastatin is an effective and well-tolerated cholesterol-lowering agent.
Humans
;
Hypercholesterolemia*
;
Male
;
Oxidoreductases
;
Pravastatin*
9.The Prevalence of Glucose-6 Phosphate Dehydrogenase Deficiency among Multi-Cultural Youths in Korea.
Hyun Ji LEE ; Kyung Hwa SHIN ; Jun Nyun KIM ; Min Ju KIM ; Hyung Hoi KIM
Korean Journal of Blood Transfusion 2018;29(1):86-89
No abstract available.
Adolescent*
;
Humans
;
Korea*
;
Oxidoreductases*
;
Prevalence*
10.Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review.
Min Woo KIM ; Hyun sun PARK ; Jong Seo PARK ; Seong Joon KOH ; Soyun CHO
Annals of Dermatology 2017;29(4):525-528
No abstract available.
Breast Neoplasms*
;
Breast*
;
Humans
;
Male
;
Oxidoreductases*
Result Analysis
Print
Save
E-mail